Prevention and treatment of osteoporosis in inflammatory bowel disease

Authors

  • Gary R. Lichtenstein MD,

    Corresponding author
    1. University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, Gastroenterology Division, Department of Medicine, Philadelphia
    • University of Pennsylvania School of Medicine, Department of Medicine, Division of Gastroenterology, 3400 Spruce St, 3rd Floor, Ravdin Bldg, Philadelphia, PA 19104–4283
    Search for more papers by this author
  • Bruce E. Sands MD, MS,

    1. Harvard Medical School, Massachusetts General Hospital, Gastrointestinal Unit and MGH IBD Center, Department of Medicine, Boston
    Search for more papers by this author
  • Michael Pazianas

    1. University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, Ralston Penn Center, Department of Medicine, Philadelphia, PA
    Search for more papers by this author

Abstract

The following are guidelines for evaluation and consideration for treatment of patients with inflammatory bone disease (IBD) after bone mineral density (BMD) measurements. The Crohn's & Colitis Foundation of America (CCFA) has indicated that its recommendations are intended to serve as reference points for clinical decision-making, not as rigid standards, limits, or rules. They should not be interpreted as quality standards.

Ancillary